Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $333.43, Implies 5% Downside

What happened

Analysts’ average 12-month price target for Charles River Laboratories International, Inc. rose from $331.29 to $333.43, based on estimates from 14 analysts. The new target implies about 5% downside from the Nov. 3 closing price; the consensus rating remains Buy among 20 analysts.

Confirmed

Global impact / market context

The higher target signals a modest improvement in analysts’ valuation expectations, but the indicated 5% downside suggests they still see the shares above their average estimate. For investors, that gap could influence expectations for potential returns, without changing the company’s revenue or costs directly.

Analyst inference

Forecasts span $295 to $390 per share, showing meaningful disagreement despite the unchanged Buy consensus. Fourteen analysts set the average target, while the broader group of 20 includes four Holds and two Sells, indicating the positive rating is not unanimous.

Confirmed

What to watch

1. Check whether subsequent analyst target updates move the $333.43 average materially, and whether the 14-analyst estimate base grows or shrinks. Analyst inference
2. Watch for changes in the Buy, Hold, and Sell counts among the 20 covering analysts; shifts would show whether the consensus view is strengthening or weakening. Analyst inference
3. Compare the share price with the target and the stated 5% downside implication, noting that the article anchors this calculation to the Nov. 3 closing price. Confirmed

Evidence

• Original source link unavailable